147 related articles for article (PubMed ID: 24040451)
1. Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate.
Araújo-Filho JL; Melo-Junior MR; Beltrão EI; de Lima LR; Antunes CB; de Carvalho LB
Int J Clin Exp Pathol; 2013; 6(9):1861-7. PubMed ID: 24040451
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of glycophenotype in prostatic neoplasm by chemiluminescent assay.
da Silva LP; de Almeida SM; de Lima LR; Cavalcanti Cde L; de Melo Lira MM; da Silva Mda P; Beltrão EI; de Carvalho Júnior LB
Int J Clin Exp Pathol; 2014; 7(7):3800-8. PubMed ID: 25120756
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
Ahmed H; Banerjee PP; Vasta GR
Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical study of the prostatic tissues with monoclonal antibody against gamma-seminoprotein. Analyses of benign prostatic hyperplasia, metastatic foci from adenocarcinoma of the prostate and malignant neoplasms other than adenocarcinoma of the prostate].
Fujino A; Shimura S; Murayama M; Ao T; Yokoyama E; Mashimo S; Ishibashi A; Koshiba K; Kuwao S
Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):527-34. PubMed ID: 7685842
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 cytotest in thyroid follicular neoplasia: a prospective, monoinstitutional study.
Pennelli G; Mian C; Pelizzo MR; Naccamulli D; Piotto A; Girelli ME; Mescoli C; Rugge M
Acta Cytol; 2009; 53(5):533-9. PubMed ID: 19798881
[TBL] [Abstract][Full Text] [Related]
6. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
[TBL] [Abstract][Full Text] [Related]
7. MAGI-2 in prostate cancer: an immunohistochemical study.
Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
[TBL] [Abstract][Full Text] [Related]
8. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.
Maygarden SJ; Strom S; Ware JL
Arch Pathol Lab Med; 1992 Mar; 116(3):269-73. PubMed ID: 1371380
[TBL] [Abstract][Full Text] [Related]
9. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
10. Zinc in the human prostate gland: normal, hyperplastic and cancerous.
Zaichick VYe ; Sviridova TV; Zaichick SV
Int Urol Nephrol; 1997; 29(5):565-74. PubMed ID: 9413764
[TBL] [Abstract][Full Text] [Related]
11. Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis.
de Melo-Júnior MR; Araújo-Filho JL; Lins CA; de Pontes-Filho NT; de Carvalho LB
Appl Biochem Biotechnol; 2010 Apr; 160(8):2198-207. PubMed ID: 19728168
[TBL] [Abstract][Full Text] [Related]
12. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
13. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
Ahmed H; Cappello F; Rodolico V; Vasta GR
Transl Oncol; 2009 Aug; 2(3):146-56. PubMed ID: 19701499
[TBL] [Abstract][Full Text] [Related]
14. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
16. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Birckbichler PJ; Bonner RB; Hurst RE; Bane BL; Pitha JV; Hemstreet GP
Cancer; 2000 Jul; 89(2):412-23. PubMed ID: 10918174
[TBL] [Abstract][Full Text] [Related]
17. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions.
Raggio E; Camandona M; Solerio D; Martino P; Franchello A; Orlandi F; Gasparri G
J Endocrinol Invest; 2010 Jun; 33(6):378-81. PubMed ID: 19625759
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma.
Nemoto R; Kawamura H; Miyakawa I; Uchida K; Hattori K; Koiso K; Harada M
J Urol; 1993 Jan; 149(1):165-9. PubMed ID: 8093265
[TBL] [Abstract][Full Text] [Related]
20. Expression of acid cysteine proteinase inhibitor (ACPI) in the normal human prostate, benign prostatic hyperplasia and adenocarcinoma.
Söderström KO; Laato M; Wu P; Hopsu-Havu VK; Nurmi M; Rinne A
Int J Cancer; 1995 Jul; 62(1):1-4. PubMed ID: 7541394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
